Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Bibliographic Details
Title: Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
Authors: Gaspar, Nathalie *, Venkatramani, Rajkumar, Hecker-Nolting, Stefanie, Melcon, Soledad Gallego, Locatelli, Franco, Bautista, Francisco, Longhi, Alessandra, Lervat, Cyril, Entz-Werle, Natacha, Casanova, Michela, Aerts, Isabelle, Strauss, Sandra J, Thebaud, Estelle, Morland, Bruce, Nieto, Adela Cañete, Marec-Berard, Perrine, Gambart, Marion, Rossig, Claudia, Okpara, Chinyere E, He, Cixin, Dutta, Lea, Campbell-Hewson, Quentin
Source: In The Lancet Oncology September 2021 22(9):1312-1321
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(21)00387-9
Published in:The Lancet Oncology
Language:English